breast cancer
Clinical collaboration announced for window of opportunity study into breast cancer
Biotechnology company, Oncolytics Biotech, has announced a clinical collaboration with an academic research group dedicated to clinical and translational research in breast cancer, SOLTI. more
Metastatic breast cancer treatment will still be available to patients despite recent guidance, says Eisai
Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. more
The top five tweets: From the BIA to breast cancer — what did EPM readers rate this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
FDA expands use of Lynparza to include breast cancer with specific inherited genetic mutation
The FDA has given the green light to an expansion of use of olaparib tablets (Lynparza) to now include the treatment of patients with certain types of breast cancer that have metastasized and whose tumours have a specific inherited genetic mutation. more
Clinical update on immunotherapy for breast cancer provided by BriaCell
An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. more
Study suggests immunotherapy may help overcome trastuzumab-resistance in breast cancer
Results from the PANACEA study, recently presented at the San Antonio Breast Cancer Symposium, have suggested that immunotherapy may help to overcome trastuzumab-resistant breast cancer. more
First biosimilar for the treatment of certain breast and stomach cancers approved by FDA
The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more
Research collaboration announced for potential new breast cancer treatments
Inflection Biosciences and the RCSI have entered into a research collaboration aiming to understand the mechanisms of resistance to major breast cancer therapies and examine potential new treatment for patients with a cancer that is unresponsive more
Two life-extending drugs now available to NHS breast cancer patients
Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more
FDA approves Lilly’s advanced or metastatic breast cancer therapy
The US FDA has approved Verzenio (abemaciclib), from Eli Lilly and Company, for the treatment of adult patients who have HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. more
PATINA trial launched to evaluate new therapeutic combination for breast cancer
The Alliance Foundation Trials (AFT) — in conjunction with Pfizer and six international cancer research groups — has launched a randomised open-label Phase III clinical study, PATINA, to evaluate a combination therapy for breast cancer. more
Fortress Diagnostics to manufacture 3N Diagnostics’ breast cancer test
An agreement has been formed by 3N Diagnostics and Fortress Diagnostics for the manufacture of the novel and patented breast cancer test, the Avisio FOXC1. more
Biosimilar receives approval recommendation from oncology committee
The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of the proposed biosimilar trastuzumab for the treatment of breast cancer. more
Researcher awarded millions to develop nanotechnology drug delivery systems
A researcher at Case Western Reserve University (CWRU) School of Medicine has been granted two awards from the National Institutes of Health (NIH) to develop nanotechnology drug delivery systems more
A deal has been struck to make Kadcyla routinely available on the NHS
NHS England has struck a deal with Roche and endorsed by the National Institute for Health and Care Excellence (NICE) to make the breast cancer drug Kadcyla available for routine use on the NHS. more
A drink a day may increase risk of breast cancer, new report reveals
World Cancer Research Fund International has released a new report that demonstrates an increased risk of breast cancer is associated with even moderate alcohol consumption. more
Diagnostic breast cancer test obtains CE Marking
A diagnostic test for an aggressive form of breast cancer, basal-like breast cancer (BLBC), has obtained CE Marking. The Avisio FOXC1 immunohistochemistry (IHC) test is available from 3N Diagnostics (3NDx). more
Pfizer gifts the NHS with breast cancer drug
Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the NHS for free for up to five months until a final decision by NICE is made. more
NICE recommends drug for breast cancer treatment
NICE has updated its guidance surrounding the treatment of post-menopausal women with a family history of breast cancer, stating that they should be offered anastrozole. more
1 in 5 women with breast cancer could benefit from existing treatment
One in five women with breast cancer could benefit from existing treatments previously thought not to be effective. more
